Back to results
US 2019/0055191 A1Published application
Adamantane derivative and use thereof
AssigneeTohoku University
InventorsShigeki MORIGUCHI, Koji FUKUNAGA, Yoshiharu IWABUCHI
Life of this patent
Estimating the term…
Abstract
The present invention provides a pharmaceutical composition for treating or preventing a cognitive disease or disorder, containing a compound represented by Formula (I), an enantiomer thereof, a diastereomer thereof, or a pharmaceutically acceptable salt thereof.
Claims13
A compound represented by Formula (I):
- wherein R1 represents a hydrogen atom or (C1-6 alkyl)carbonyl optionally substituted with one or more halogen atoms;
- R2 represents a hydrogen atom or (C1-6 alkyl)carbonyl optionally substituted with one or more halogen atoms;
- X represents O or NR5;
- R3 represents phenyl optionally substituted with one or more substituents selected from X1, 5- or 6-membered heteroaryl optionally substituted with one or more substituents selected from X1, or COOR6;
- R4 represents a hydrogen atom, a halogen atom, azido, —OR7 or —NHR8;
- R5 represents a hydrogen atom or C1-6 alkyl;
- R6 represents a hydrogen atom or C1-6 alkyl;
- R7 represents a hydrogen atom, C1-6 alkyl, C1-6 alkoxy-C1-6 alkyl or (C1-6 alkyl)carbonyl optionally substituted with one or more halogen atoms;
- R8 represents a hydrogen atom, C1-6 alkyl or (C1-6 alkyl)carbonyl optionally substituted with one or more halogen atoms;
- and
- X1 represents C1-6 alkyl, a halogen atom, C1-6 alkoxy, nitro or cyano,
- an enantiomer thereof, a diastereomer thereof, or a pharmaceutically acceptable salt thereof.
9 more elements
Dependencies are inferred from the claim text.